Internal and Emergency Medicine

, Volume 3, Issue 3, pp 197–200 | Cite as

Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No

IM - Debate

References

  1. 1.
    Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306PubMedCrossRefGoogle Scholar
  2. 2.
    Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853PubMedCrossRefGoogle Scholar
  3. 3.
    Patrono C, Coller B, FitzGerald GA et al (2004) Platelet-active drugs: the relationship among dose, effectiveness and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:234S–264SPubMedCrossRefGoogle Scholar
  4. 4.
    Landolfi R, Marchioli R, Kutti J et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114–124PubMedCrossRefGoogle Scholar
  5. 5.
    Giron-Gonzales JA, Garcia del Rio E, Rodriguez C et al (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31:1560–1567Google Scholar
  6. 6.
    Forastiero R, Martinuzzo M, Pombo G et al (2005) A prospective study of antibodies to β2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 3:1231–1238PubMedCrossRefGoogle Scholar
  7. 7.
    Shah NM, Khamashta MA, Atsumi T et al (1998) Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7:3–6PubMedCrossRefGoogle Scholar
  8. 8.
    Somers E, Magder LS, Petri M (2002) Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29:2531–2536PubMedGoogle Scholar
  9. 9.
    Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian registry. Am J Med 100:530–536PubMedCrossRefGoogle Scholar
  10. 10.
    Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997PubMedCrossRefGoogle Scholar
  11. 11.
    Kaul M, Erkan D, Sammaritano L et al (2007) Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66:927–930PubMedCrossRefGoogle Scholar
  12. 12.
    Ginsburg KS, Liang MH, Newcomer L et al (1992) Anticardiolipn antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997–1002PubMedGoogle Scholar
  13. 13.
    Wahl DG, Bounameaux H, de Moerloose P et al (2000) Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160:2042–2048PubMedCrossRefGoogle Scholar
  14. 14.
    Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum 56:2382–2391PubMedCrossRefGoogle Scholar
  15. 15.
    Galli M, Borrelli G, Jacobsen EM et al (2007) Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110:1178–1183PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  1. 1.Servizio di Immunoematologia e Medicina Trasfusionale e Centro EmostasiOspedali Riuniti di BergamoBergamoItaly

Personalised recommendations